Glaukos is transforming the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs.
Who We Are
Glaukos is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal disease.
Innovation is at the core of everything we do. Our mission at Glaukos is to truly transform vision by pioneering novel, dropless platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases. Our mantra “We’ll Go First” embodies our commitment and determination to take chances and push the limits of science and technology to disrupt and improve the legacy treatment paradigms in glaucoma, corneal disorders and retinal diseases.
Glaukos Corporate Overview
Founded in 1998, Glaukos is an ophthalmic medical technology and pharmaceutical company focused on developing and commercialising novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.
Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is located in Aliso Viejo, California, and we have additional locations in the United States, Canada, United Kingdom, Germany, Japan, Australia and Brazil.
We’ll Go First
Glaukos is committed to investing in the future of ophthalmology to transform standards of care and improve patient lives. Our dedicated commitment to continuous innovation has resulted in an unrivaled pipeline of novel therapies.
We’re proud of the corporate citizenship efforts of the Glaukos Charitable Foundation, Company and employees, and pledge to continue this important work in helping improve the lives of those suffering and in need.
Careers at Glaukos
Help put the next wave of disruptive glaucoma technologies on the market.
Work with a team that’s dedicated to combatting a leading cause of blindness.